Table 1 Baseline clinicopathologic variables of patients with advanced urothelial carcinoma who received immune checkpoint inhibitors.
Variables | Overall | Second-line or later pembrolizumab | Maintenance avelumab | Adjuvant nivolumab |
|---|---|---|---|---|
Total, n | 42 | 19 | 13 | 10 |
Age, years, mean ± SD | 74.6 ± 8.7 | 71.1 ± 10.2 | 75.6 ± 6.1 | 80.0 ± 5.1 |
Sex | ||||
Male | 31 (74%) | 16 (84%) | 10 (77%) | 5 (50%) |
Female | 11 (26%) | 3 (16%) | 3 (23%) | 5 (50%) |
ECOG-PS | ||||
0 | 33 (79%) | 16 (84%) | 12 (92%) | 5 (50%) |
1 | 8 (19%) | 3 (16%) | 1 (7.7%) | 4 (40%) |
2 | 1 (2.4%) | 0 | 0 | 1 (10%) |
Smoking | ||||
Never | 13 (31%) | 4 (21%) | 5 (39%) | 4 (40%) |
Former | 20 (48%) | 11 (58%) | 4 (31%) | 5 (50%) |
Current | 6 (14%) | 3 (16%) | 3 (23%) | 0 |
Unknown | 3 (7.1%) | 1 (5.3%) | 1 (7.7%) | 1 (10%) |
eGFR, mL/min/1.73m2, mean ± SD | 47.1 ± 18.7 | 50.2 ± 12.7 | 52.0 ± 25.8 | 35.9 ± 10.4 |
Primary disease | ||||
Bladder | 21 (50%) | 10 (53%) | 8 (62%) | 3 (30%) |
Renal pelvis | 14 (33%) | 6 (32%) | 4 (31%) | 4 (40%) |
Ureter | 7 (17%) | 3 (16%) | 1 (7.7%) | 3 (30%) |
Radical surgery | ||||
Cystectomy | 14 (33%) | 6 (32%) | 5 (39%) | 3 (30%) |
Nephroureterectomy | 17 (41%) | 7 (37%) | 3 (23%) | 7 (70%) |
No | 11 (26%) | 6 (32%) | 5 (39%) | 0 |
Unresectable/metastatis lesions# | ||||
Primary disease | 8 (19%) | 6 (32%) | 2 (15%) | 0 |
Local recurrence arround primary disease | 8 (19%) | 2 (11%) | 6 (46%) | 0 |
Lymph nodes | 21 (50%) | 13 (68%) | 8 (62%) | 0 |
Lung | 10 (24%) | 6 (32%) | 4 (31%) | 0 |
Liver | 3 (7.1%) | 1 (5.3%) | 2 (15%) | 0 |
Bone | 6 (14%) | 5 (26%) | 1 (7.7%) | 0 |
Peritonium | 1 (2.4%) | 0 | 1 (7.7%) | 0 |
